Clinical Trial Update: Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial results report on the efficacy and safety of Daewoong's DWC202404 and DWC202314 in hypertension, with the study now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension
• Hypertension

Drugs mentioned

• DWC202314
• DWC202404

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Hypertension, Essential Hypertension | Phase 3 | Status: COMPLETED